{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:00:30Z","timestamp":1793642430599,"version":"4.5.1"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Since the TGN1412 clinical trial failure to predict cytokine release syndrome (CRS) during preclinical trials, alternative\n                    <jats:italic>in vitro<\/jats:italic>\n                    models have become increasingly important for identifying potential adverse outcomes in early drug development. Considering this, in 2019 the IMI2\/EU immune safety avatar (imSAVAR) consortium was established, encompassing academic, industry, and regulatory organizations. ImSAVAR aims to deliver a broad range of tools to enhance our ability to assess the efficacy and safety of immunomodulatory therapies. In addition, imSAVAR uses the adverse outcome pathway (AOP) concept to describe immune-related adverse effects, such as CRS, thereby facilitating the discovery of new biological markers for clinical management and prediction of immune-related adverse effects in nonclinical development. ImSAVAR unanimously agreed that CRS and advanced cytokine release assay (CRA) development is a key focus with regards to immunological safety testing and hazard identification. The CRA field has rapidly accelerated in recent years, with the rise of New Approach Methodologies (NAMs) to provide enhanced predictive immunological safety testing within a clinical setting. Here, we provide an up-to-date review of recent developments of advanced,\n                    <jats:italic>in vitro<\/jats:italic>\n                    CRA models, discuss how these advances may impact the future field of nonclinical toxicology and the understanding of immune-related adverse outcomes and offer guidance on appropriate model selection.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1732193","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:40:56Z","timestamp":1767940856000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Perspective of using in vitro models to understand immunotherapy-induced cytokine release syndrome"],"prefix":"10.3389","volume":"16","author":[{"given":"Ethan","family":"Perkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Alb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Fogal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Mazein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Ostaszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherina","family":"Sewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"Astct consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-cd28 monoclonal antibody tgn1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"New Engl J Med"},{"key":"B4","article-title":"Opdivo (nivolumab): Second pd-1 inhibitor receives fda approval for unresectable or metastatic melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-15-0612","article-title":"Fda approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac054","article-title":"Fda approval summary: Axicabtagene ciloleucel for relapsed or refractory follicular lymphoma","volume":"27","author":"Bouchkouj","year":"2022","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified t cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-2035","article-title":"Fda approval summary: Tisagenlecleucel for treatment of patients with relapsed or refractory b-cell precursor acute lymphoblastic leukemia","volume":"25","author":"O'Leary","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"Car-t cell therapy: The efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147652","article-title":"Cytokine release syndrome associated with t-cell-based therapies for hematological Malignancies: Pathophysiology, clinical presentation, and treatment","volume":"22","author":"Cosenza","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807050","article-title":"Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: A case series of 25 patients and review of the literature","volume":"13","author":"Tay","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B14","unstructured":"Immune safety avatar\n          \n          \n          \n          2019"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.intimp.2017.10.021","article-title":"Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics","volume":"54","author":"Fletcher","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2365","article-title":"A role for interleukin-2 trans-presentation in dendritic cell-mediated t cell activation in humans, as revealed by daclizumab therapy","volume":"17","author":"Wuest","year":"2011","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits t-cell receptor-mediated t-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e50068","DOI":"10.1371\/journal.pone.0050068","article-title":"Gfp affects human t cell activation and cytokine production following in vitro stimulation","volume":"8","author":"Koelsch","year":"2013","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.5.3325","article-title":"Cytokine storm\u201d in the phase i trial of monoclonal antibody tgn1412: Better understanding the causes to improve preclinical testing of immunotherapeutics","volume":"179","author":"Stebbings","year":"2007","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2016.06.006","article-title":"Cytokine release: A workshop proceedings on the state-of-the-science, current challenges and future directions","volume":"85","author":"Grimaldi","year":"2016","journal-title":"Cytokine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2013.12.009","article-title":"Cytokine release assays: Current practices and future directions","volume":"66","author":"Finco","year":"2014","journal-title":"Cytokine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytox.2020.100042","article-title":"Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - report of an international collaborative study","volume":"2","author":"Vessillier","year":"2020","journal-title":"Cytokine X"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2011.03.019","article-title":"Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody tgn1412 in culture","volume":"55","author":"Findlay","year":"2011","journal-title":"Cytokine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2022.113231","article-title":"Development of a flow cytometry-based potency assay for prediction of cytokine storms induced by biosimilar monoclonal antibodies","volume":"502","author":"Madsen","year":"2022","journal-title":"J Immunol Methods"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01851","article-title":"A flow cytometry-based whole blood natural killer cell cytotoxicity assay using overnight cytokine activation","volume":"11","author":"Kim","year":"2020","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703472","article-title":"Fk506 potently inhibits t cell activation induced tnf-alpha and il-1beta production in vitro by human peripheral blood mononuclear cells","volume":"130","author":"Sakuma","year":"2000","journal-title":"Br J Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-319780","article-title":"Preculture of pbmcs at high cell density increases sensitivity of t-cell responses, revealing cytokine release by cd28 superagonist tgn1412","volume":"118","author":"R\u00f6mer","year":"2011","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1440-1681.2007.04755.x","article-title":"Induction of inflammatory cytokine release from human umbilical vein endothelial cells by agonists of proteinase-activated receptor-2","volume":"35","author":"Niu","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified t cells derived from defined cd8+ and cd4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.22074\/cellj.2023.2001712.1304","article-title":"Characterization of car t cells manufactured using genetically engineered artificial antigen presenting cells","volume":"25","author":"Sayadmanesh","year":"2023","journal-title":"Cell J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.082248","article-title":"Blinatumomab induces autologous t-cell killing of chronic lymphocytic leukemia cells","volume":"98","author":"Wong","year":"2013","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.388","article-title":"A novel bcma\/cd3 bispecific t-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1096\/fj.14-268144","article-title":"An autologous endothelial cell:Peripheral blood mononuclear cell assay that detects cytokine storm responses to biologics","volume":"29","author":"Reed","year":"2015","journal-title":"FASEB J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e022795","DOI":"10.1161\/jaha.121.022795","article-title":"Comparative analysis of blood-derived endothelial cells for designing next-generation personalized organ-on-chips","volume":"10","author":"Mathur","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1039\/c9lc00469f","article-title":"Organ-on-chips made of blood: Endothelial progenitor cells from blood reconstitute vascular thromboinflammation in vessel-chips","volume":"19","author":"Mathur","year":"2019","journal-title":"Lab Chip"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-bioeng-082420-124920","article-title":"Modeling immunity in vitro: Slices, chips, and engineered tissues","volume":"23","author":"Hammel","year":"2021","journal-title":"Annu Rev BioMed Eng"},{"key":"B37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/026119290903701s05","article-title":"An immunologic model for rapid vaccine assessment \u2013 a clinical trial in a test tube","author":"Higbee","year":"2009","journal-title":"Altern Lab Anim"},{"key":"B38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/1547691x.2011.613419","article-title":"A predictive biomimetic model of cytokine release induced by tgn1412 and other therapeutic monoclonal antibodies","volume":"9","author":"Dhir","year":"2012","journal-title":"J Immunotoxicol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e0197478","DOI":"10.1371\/journal.pone.0197478","article-title":"Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune model","volume":"13","author":"Luna","year":"2018","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1177\/1076029614562037","article-title":"Evaluation of immunostimulatory potential of branded and us-generic enoxaparins in an in vitro human immune system model","volume":"21","author":"Luna","year":"2015","journal-title":"Clin Appl Thromb Hemost"},{"key":"B41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1089\/dst.2012.0006","article-title":"In vitro biomimetic model of the human immune system for predictive vaccine assessments","volume":"1","author":"Drake","year":"2012","journal-title":"Disruptive Sci Technol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/1547691X.2024.2378729","article-title":"Identifying cd19-targeted car-t cell immune pathways in an in vitro human immune mimetic cytokine release assay","volume":"21","author":"Dinh-Le","year":"2024","journal-title":"J Immunotoxicology"},{"key":"B43","unstructured":"National centre of replacement, refinement and reduction of animals crack it challenge 44 - sensoochip\n          \n          \n          \n          2023"},{"key":"B44","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s42003-023-04434-9","article-title":"A high-throughput, 28-day, microfluidic model of gingival tissue inflammation and recovery","volume":"6","author":"Gard","year":"2023","journal-title":"Commun Biol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"14961","DOI":"10.1038\/s41598-021-94095-7","article-title":"High-throughput human primary cell-based airway model for evaluating influenza, coronavirus, or other respiratory viruses in vitro","volume":"11","author":"Gard","year":"2021","journal-title":"Sci Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1039\/D1LC00067E","article-title":"High-throughput organ-on-chip platform with integrated programmable fluid flow and real-time sensing for complex tissue models in drug development workflows","volume":"21","author":"Azizgolshani","year":"2021","journal-title":"Lab Chip"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e2103241","DOI":"10.1002\/advs.202103241","article-title":"Ectopic lymphoid follicle formation and human seasonal influenza vaccination responses recapitulated in an organ-on-a-chip","volume":"9","author":"Goyal","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"B48","unstructured":"Nonclinical evaluation of the immunotoxic potential of pharmaceuticals\n          \n          \n          \n          2023"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003486","article-title":"Time to evolve: Predicting engineered t cell-associated toxicity with next-generation models","volume":"10","author":"Donnadieu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158057","article-title":"In vivo pbmc-humanized mouse model to assess individual variability in efficacy and toxicity of autologous and allogeneic chimeric antigen receptor t-cell immunotherapy","volume":"140","author":"Lee","year":"2022","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2021.105064","article-title":"Nonclinical safety assessment of engineered t cell therapies","volume":"127","author":"Lebrec","year":"2021","journal-title":"Regul Toxicol Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.addr.2021.03.015","article-title":"Immunocompetent cancer-on-chip models to assess immuno-oncology therapy","volume":"173","author":"Maulana","year":"2021","journal-title":"Adv Drug Delivery Rev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"Iii","DOI":"10.1385\/1592590497","article-title":"The elisa guidebook","volume":"149","author":"Crowther","year":"2000","journal-title":"Methods Mol Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/sj.icb.7100062","article-title":"The advent of the cytokine storm","volume":"85","author":"Clark","year":"2007","journal-title":"Immunol Cell Biol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with t-cell-engaging bispecific antibodies: Current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/sj.icb.7100042","article-title":"Polymorphisms of cd3epsilon in cynomolgus and rhesus monkeys and their relevance to anti-cd3 antibodies and immunotoxins","volume":"85","author":"Liu","year":"2007","journal-title":"Immunol Cell Biol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.clim.2006.10.014","article-title":"Transient regulatory t-cells: A state attained by all activated human t-cells","volume":"123","author":"Pillai","year":"2007","journal-title":"Clin Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"867015","DOI":"10.3389\/fimmu.2022.867015","article-title":"A Comprehensive Atlas of Immunological Differences Between Humans, Mice, and Non-Human Primates","volume":"13","author":"Bjornson-Hooper","year":"2022","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00079","article-title":"Control of cytokine production by human fc gamma receptors: Implications for pathogen defense and autoimmunity","volume":"6","author":"Vogelpoel","year":"2015","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e53384","DOI":"10.3791\/53384","article-title":"Generation and culture of blood outgrowth endothelial cells from human peripheral blood","author":"Ormiston","year":"2015","journal-title":"J Vis Exp"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107226","article-title":"Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from cll patients","volume":"90","author":"Eltahir","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.9b06860","article-title":"Use of epialveolar lung model to predict fibrotic potential of multiwalled carbon nanotubes","volume":"14","author":"Barosova","year":"2020","journal-title":"ACS Nano"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2010.11.009","article-title":"Evaluation of tissue engineered models of the oral mucosa to investigate oral candidiasis","volume":"50","author":"Yadev","year":"2011","journal-title":"Microb Pathog"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2023.03.033","article-title":"The fda modernization act 2.0: Drug testing in animals is rendered optional","volume":"136","author":"Adashi","year":"2023","journal-title":"Am J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-022-00466-9","article-title":"Human organs-on-chips for disease modelling, drug development and personalized medicine","volume":"23","author":"Ingber","year":"2022","journal-title":"Nat Rev Genet"},{"key":"B67","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.stem.2024.04.018","article-title":"Breast cancer-on-chip for patient-specific efficacy and safety testing of car-t cells","volume":"31","author":"Maulana","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201801531","article-title":"Ex vivo dynamics of human glioblastoma cells in a microvasculature-on-a-chip system correlates with tumor heterogeneity and subtypes","volume":"6","author":"Xiao","year":"2019","journal-title":"Advanced Sci"},{"key":"B69","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25126496","article-title":"Modeling of Blood-Brain Barrier (BBB) Dysfunction and Immune Cell Migration Using Human BBB-on-a-Chip for Drug Discovery Research","volume":"25","author":"Ohbuchi","year":"2024","journal-title":"Int J Mol Sci."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/aor.14503","article-title":"Fda modernization act 2.0 allows for alternatives to animal testing","volume":"47","author":"Han","year":"2023","journal-title":"Artif Organs"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02690-0","article-title":"Fda pushes to replace animal testing","volume":"43","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2021.1945803","article-title":"Pre-clinical development of a novel cd3-cd123 bispecific t-cell engager using cross-over dual-variable domain (codv) format for acute myeloid leukemia (aml) treatment","volume":"10","author":"Bonnevaux","year":"2021","journal-title":"Oncoimmunology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"10976","DOI":"10.1038\/s41598-022-14726-5","article-title":"Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific t cell engager in multiple myeloma","volume":"12","author":"Abrams","year":"2022","journal-title":"Sci Rep"},{"key":"B74","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1128\/mmbr.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol Mol Biol Rev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-022-09842-9","article-title":"In vitro grafting of hepatic spheroids and organoids on a microfluidic vascular bed","volume":"25","author":"Bonanini","year":"2022","journal-title":"Angiogenesis"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.67106","article-title":"Human immunocompetent organ-on-chip platforms allow safety profiling of tumor-targeted t-cell bispecific antibodies","volume":"10","author":"Kerns","year":"2021","journal-title":"Elife"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2023.115247","article-title":"A digital nanoplasmonic microarray immunosensor for multiplexed cytokine monitoring during car t-cell therapy from a leukemia tumor microenvironment model","volume":"230","author":"Ma","year":"2023","journal-title":"Biosens Bioelectron"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2017.018","article-title":"On-chip human microvasculature assay for visualization and quantification of tumor cell extravasation dynamics","volume":"12","author":"Chen","year":"2017","journal-title":"Nat Protoc"},{"key":"B79","doi-asserted-by":"publisher","first-page":"12225","DOI":"10.1038\/s41598-021-90833-z","article-title":"A high-throughput microfluidic bilayer co-culture platform to study endothelial-pericyte interactions","volume":"11","author":"Rogers","year":"2021","journal-title":"Sci Rep"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2021.1884248","article-title":"Cytokine release syndrome in covid-19: A major mechanism of morbidity and mortality","volume":"41","author":"Que","year":"2022","journal-title":"Int Rev Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002392","article-title":"Shared inflammatory pathways and therapeutic strategies in covid-19 and cancer immunotherapy","volume":"9","author":"Iovino","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1126\/science.1188302","article-title":"Reconstituting organ-level lung functions on a chip","volume":"328","author":"Huh","year":"2010","journal-title":"Science"},{"key":"B83","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s43856-022-00209-1","article-title":"Performance assessment and economic analysis of a human liver-chip for predictive toxicology","volume":"2","author":"Ewart","year":"2022","journal-title":"Commun Med"},{"key":"B84","unstructured":"Vallance\n              P\n            \n            \n              Hanson\n              D\n            \n            \n              Hayman\n              S\n            \n          \n          \n          2025"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.AC119.007558","article-title":"Granulocyte-macrophage colony-stimulating factor inactivation in car t-cells prevents monocyte-dependent release of key cytokine release syndrome mediators","volume":"294","author":"Sachdeva","year":"2019","journal-title":"J Biol Chem"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax5516","article-title":"Reproducing human and cross-species drug toxicities using a liver-chip","volume":"11","author":"Jang","year":"2019","journal-title":"Sci Transl Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v13.i12.2005","article-title":"Liver dysfunction as a cytokine storm manifestation and prognostic factor for severe covid-19","volume":"13","author":"Taneva","year":"2021","journal-title":"World J Hepatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1732193\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:40:58Z","timestamp":1767940858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1732193\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":87,"alternative-id":["10.3389\/fimmu.2025.1732193"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1732193","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"1732193"}}